FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2327590919> ?p ?o ?g. }

• W2327590919 endingPage "234" @default.
• W2327590919 startingPage "233.3" @default.
• W2327590919 abstract "<h3>Background</h3> Thyroid cancer typically has a good outcome following standard treatments, which include surgery or radioactive iodine or systemic chemotherapy. During the last two years many randomised trials have demonstrated that multikinase inhibitors, such as sunitinib, are active in metastatic thyroid carcinoma. In Italy, sunitinib is only approved for the treatment of metastatic renal carcinoma, GIST (gastrointestinal stromal tumour) or HCC (hepatocellular carcinoma), but if there are no other valid therapeutic options a Sicilian regional law allows clinicians to prescribe an off-label treatment and hospital pharmacies to dispense it. <h3>Purpose</h3> To evaluate the treatment of a multikinase inhibitor, sunitinib, for an off-label indication and to assess the safety and efficacy of the treatment for an older patient, female, 80 years old, with metastatic thyroid cancer not responsive to cisplatin/epirubicin and gemcitabine. <h3>Materials and methods</h3> The oncologist prepared a formal request, with the patient9s informed consent and all the phase II and III trials available in literature. These documents were also evaluated by the hospital pharmacist and then finally approved by the hospital9s medical director. After this procedure the pharmacy supplied and distributed the drug to the patient who was being treated at home. <h3>Results</h3> Since April 2011, the patient took sunitinib at the standard dose of 50 mg/day for 8 weeks and the volume of the lesion reduced. The clinician monitored vigilantly for hypertension. Fatigue was the side effect that led to a reduction of dose to 25 mg/day for another 8 weeks. At present, six months later, the disease has regressed further. <h3>Conclusions</h3> Our data support the use of sunitinib in metastatic thyroid cancer, demonstrating also a low incidence of adverse reactions. This case report can also demonstrate the advantages of using off-label treatments if they are supported by valid clinical evidence rather than updating the regulatory approval of some drugs." @default.
• W2327590919 created "2016-06-24" @default.
• W2327590919 creator A5058176815 @default.
• W2327590919 creator A5075338390 @default.
• W2327590919 creator A5081061708 @default.
• W2327590919 creator A5083038373 @default.
• W2327590919 date "2012-03-12" @default.
• W2327590919 modified "2023-09-27" @default.
• W2327590919 title "The use of sunitinib in metastatic thyroid carcinoma: case report of an off-label treatment" @default.
• W2327590919 doi "https://doi.org/10.1136/ejhpharm-2012-000074.389" @default.
• W2327590919 hasPublicationYear "2012" @default.
• W2327590919 type Work @default.
• W2327590919 sameAs 2327590919 @default.
• W2327590919 citedByCount "0" @default.
• W2327590919 crossrefType "journal-article" @default.
• W2327590919 hasAuthorship W2327590919A5058176815 @default.
• W2327590919 hasAuthorship W2327590919A5075338390 @default.
• W2327590919 hasAuthorship W2327590919A5081061708 @default.
• W2327590919 hasAuthorship W2327590919A5083038373 @default.
• W2327590919 hasConcept C121608353 @default.
• W2327590919 hasConcept C126322002 @default.
• W2327590919 hasConcept C141071460 @default.
• W2327590919 hasConcept C143998085 @default.
• W2327590919 hasConcept C2776264508 @default.
• W2327590919 hasConcept C2778019345 @default.
• W2327590919 hasConcept C2778695046 @default.
• W2327590919 hasConcept C2779490328 @default.
• W2327590919 hasConcept C2779761222 @default.
• W2327590919 hasConcept C71924100 @default.
• W2327590919 hasConceptScore W2327590919C121608353 @default.
• W2327590919 hasConceptScore W2327590919C126322002 @default.
• W2327590919 hasConceptScore W2327590919C141071460 @default.
• W2327590919 hasConceptScore W2327590919C143998085 @default.
• W2327590919 hasConceptScore W2327590919C2776264508 @default.
• W2327590919 hasConceptScore W2327590919C2778019345 @default.
• W2327590919 hasConceptScore W2327590919C2778695046 @default.
• W2327590919 hasConceptScore W2327590919C2779490328 @default.
• W2327590919 hasConceptScore W2327590919C2779761222 @default.
• W2327590919 hasConceptScore W2327590919C71924100 @default.
• W2327590919 hasIssue "2" @default.
• W2327590919 hasLocation W23275909191 @default.
• W2327590919 hasOpenAccess W2327590919 @default.
• W2327590919 hasPrimaryLocation W23275909191 @default.
• W2327590919 hasRelatedWork W2036852888 @default.
• W2327590919 hasRelatedWork W2116758310 @default.
• W2327590919 hasRelatedWork W2339755730 @default.
• W2327590919 hasRelatedWork W2402089364 @default.
• W2327590919 hasRelatedWork W2433065005 @default.
• W2327590919 hasRelatedWork W2893444911 @default.
• W2327590919 hasRelatedWork W2967372420 @default.
• W2327590919 hasRelatedWork W2996143563 @default.
• W2327590919 hasRelatedWork W3183971356 @default.
• W2327590919 hasRelatedWork W4250652343 @default.
• W2327590919 hasVolume "19" @default.
• W2327590919 isParatext "false" @default.
• W2327590919 isRetracted "false" @default.
• W2327590919 magId "2327590919" @default.
• W2327590919 workType "article" @default.